Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer

British Journal of Cancer

Volumn 107, Issue 11, 2012, Pages 1853-1863

  Nitzsche, B ^a   Gloesenkamp, C ^a   Schrader, M ^b   Hoffmann, B ^a   Zengerling, F ^b   Balabanov, S ^c   Honecker, F ^d   Hopfner M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

chick chorioallantoic membrane assay; cisplatin; resistance; testicular germ cell tumour; tumour angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; DNA TOPOISOMERASE; FIBROBLAST GROWTH FACTOR 2; GADD45B PROTEIN; HP 14; HP 2; PROTEIN; PROTEIN DNAJ; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CHICKEN; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; GENE EXPRESSION PROFILING; GERM CELL TUMOR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CHICK EMBRYO; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOVASCULARIZATION, PATHOLOGIC; TESTICULAR NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84870032370     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.481     Document Type: Article

References (49)

1. Adam M, Schmidt D, Wardelmann E, Wernert N, Albers P (2003) Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol 44: 329-336
2. Azoitei N, Pusapati GV, Kleger A, Möller P, Küfer R, Genze F, Wagner M, van Lint J, Carmeliet P, Adler G, Seufferlein T (2010) Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 59(10): 1316-1330
3. Bentas W, Beecken W-D, Glienke W, Binder J, Schuldes H (2003) Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors. Urol Res 30: 390-393
4. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I, Kollmannsberger C (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatinrefractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19: 448-453
5. Castillo-Á vila W, Piulats JM, Garcia del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F (2009) Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 15: 3384-3395
6. Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW (1984) The functional human dihydrofolate reductase gene. J Biol Chem 259: 3933-3943
7. Chlench S, Mecha Disassa N, Hohberg M, Hoffmann C, Pohlkamp T, Beyer G, Bongrazio M, Da Silva-Azevedo L, Baum O, Pries AR, Zakrzewicz A (2007) Regulation of Foxo-1 and the angiopoietin-2/Tie2 system by shear stress. FEBS Lett 581: 673-680
8. De Wit R, Skoneczna IA, Gedske Daugaard K, de Santis M, Garin A, Aass N, Witjes JA, Albers P, White J, Germa-Lluch JR, Osanto S, Marreaud S, Collette L (2011) A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): an intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). ASCO 29: 4509
9. Devouassoux-Shisheboran M, Mauduit C, Tabone E, Droz JP, Benahmed M (2003) Growth regulatory factors and signalling proteins in testicular germ cell tumours. APMIS 111: 212-224 discussion 224
10. Einhorn LH, Brames MJ, Juliar B, Williams SD (2007) Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 25: 513-516
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318
12. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. J Am Med Assoc 299: 672-684
13. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
14. Fried J, Perez AG, Clarkson BD (1976) Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. J Cell Biol 71: 172-181
15. Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, Take S, Nishiyama K, Yonezawa S, Akiba S, Akiyama S-i, Ohi Y (1999) Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 85: 1323-1330
16. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883
17. Gillies RJ, Didier N, Denton M (1986) Determination of cell number in monolayer cultures. Anal Biochem 159: 109-113
18. Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M (2012a) Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol 40(5): 1659-1667
19. Gloesenkamp CR, Nitzsche B, Ocker M, Di Fazio P, Quint K, Hoffmann B, Scherübl H, Höpfner M (2012b) AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol 40(3): 876-888
20. Honecker F, Wermann H, Mayer F, Gillis AJM, Stoop H, van Gurp RJLM, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WNM, Oosterhuis JW, Bokemeyer C, Looijenga LHJ (2009) Microsatellite instability, mismatch repair deficiency, and Braf mutation in treatment-resistant germ cell tumors. J Clin Oncol 27: 2129-2136
21. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS (1998) Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16: 2345-2349
22. Huang DW, Sherman BT, Lempicki RA (2009a) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57
23. Huang DW, Sherman BT, Lempicki RA (2009b) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13
24. Jensen DE, Black AR, Swick AG, Azizkhan JC (1997) Distinct roles for Sp1 and E2F sites in the growth/cell cycle regulation of the DHFR promoter. J Cell Biochem 67: 24-31
25. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Turley H, Valtola R, Bicknell R, Harris AL (2000) Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. BJU Int 86: 80-86
26. Köberle B, Tomicic MT, Usanova S, Kaina B (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806: 172-182
27. Kollmannsberger C, Nichols C, Bokemeyer C (2006) Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 106: 1217-1226
28. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120: 3594-3605
29. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S (2011) Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2: e148
30. Masters JR, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H (1996) Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A: 1248-1253
31. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LHJ, Bokemeyer C (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9: 767-773
32. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24
33. Nitzsche B, Glösenkamp C, Schrader M, Ocker M, Preissner R, Lein M, Zakrzewicz A, Hoffmann B, Höpfner M (2010) Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 103: 18-28
34. Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T, Xue L, McIntyre A, Shan L, Powles T, Oliver RTD, Young BD, Shipley J, Berney DM, Joel SP, Lu Y-J (2010) The Association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol 176: 2607-2615
35. Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C, Kollmannsberger C (2011a) Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann OncolE 22: 2654-2660
36. Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, Boehlke I, Bokemeyer C (2011b) Long-Term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 60: 850-855
37. Oliveros JC (2007) VENNY. An interactive tool for comparing lists with Venn Diagrams (http://bioinfogp.cnb.csic.es/tools/venny/index.html
38. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F, Abend M (2011) Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 10: 52
39. Ramasubbaiah R, Brames J, Johnston EL, Einhorn LH, Vaughn DJ, Perkins SM (2010) Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT). ASCO 28: e15054
40. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428
41. Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH, de Vries EG (1995) Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 71: 684-690
42. Schrader M, Kempkensteffen C, Christoph F, Hinz S, Weikert S, Lein M, Krause H, Stefan C, Jung K, Höpfner M, Albers P, Miller K, Schostak M (2009) Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. Oncology 76: 77-84
43. Suddek GM (2011) Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals. Cancer Chemother Pharmacol 67: 1035-1044
44. Takano H, Murasawa S, Asahara T (2008) Functional and gene expression analysis of hTERT overexpressed endothelial cells. Biol Targets Ther 2: 547-554
45. Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, Lago CT, Califano D, Monaco C, Mineo A, Santelli G, Manzo G, Botti G, Chiappetta G, Persico MG (1996) Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 13: 577-587
46. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin K-M, Fulda S (2008) Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 68: 7956-7965
47. Wang N, Trend B, Bronson DL, Fraley EE (1980) Nonrandom abnormalities in chromosome 1 in human testicular cancers. Cancer Res 40: 796-802
48. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ, Harris CC (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci 96: 3706-3711
49. Zhan Q (2005) Gadd45a, a p53-and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res 569: 133-143